Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1021 to 1035 of 1308 results for social care

  1. Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

    Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.

  2. Is acupuncture effective in reducing alcohol consumption compared with standard care?

    acupuncture effective in reducing alcohol consumption compared with standard care? Any explanatory notes(if applicable) Why this is...

  3. Public board meeting agenda and papers: July 2024

    Agenda and papers of the NICE public board meeting on 17 July 2024

  4. Public board meeting agenda and papers: March 2026

    Agenda and papers of the NICE public board meeting on 18 March 2026

  5. Public board meeting agenda and papers: May 2023

    Agenda and papers of the NICE public board meeting on 17 May 2023

  6. Public board meeting agenda and papers: December 2022

    Agenda and papers of the NICE public board meeting on 16 December 2022

  7. Ofatumumab for treating relapsing multiple sclerosis (TA699)

    Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.

  8. Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions (MIB15)

    NICE has developed a Medtech Innovation Briefing (MIB) on Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions

  9. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    Discontinued Reference number: GID-TA11041

  10. Otovent nasal balloon for otitis media with effusion (MIB59)

    NICE has developed a medtech innovation briefing (MIB) on the Otovent nasal balloon for otitis media with effusion

  11. Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

    Discontinued Reference number: GID-TA10416

  12. Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]

    In development Reference number: GID-TA10696 Expected publication date: TBC

  13. Public board meeting agenda and papers: December 2024

    Agenda and papers of the NICE public board meeting on 11 December 2024

  14. Public board meeting agenda and papers: May 2024

    Agenda and papers of the NICE public board meeting on 15 May 2024

  15. Public board meeting agenda and papers: July 2022

    Agenda and papers of the NICE public board meeting on 22 July